

Extrapyramidal symptom profiles in Japanese patients on olanzapine or haloperidol

Schizophrenia Research

57, 227-238

DOI: [10.1016/s0920-9964\(01\)00314-0](https://doi.org/10.1016/s0920-9964(01)00314-0)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2003, 120B, 35-39.	2.4	64
3	Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. <i>Psychiatric Genetics</i> , 2003, 13, 163-168.	0.6	35
4	Quetiapine Treatment for Behavioral and Psychological Symptoms in Patients with Senile Dementia of Alzheimer Type. <i>Neuropsychobiology</i> , 2004, 49, 201-204.	0.9	37
5	Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 268-273.	1.0	8
6	Switch from Risperidone to Perospirone in Patients with Chronic Schizophrenia. <i>Clinical Drug Investigation</i> , 2004, 24, 295-299.	1.1	3
7	Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. <i>Current Therapeutic Research</i> , 2004, 65, 57-69.	0.5	1
8	Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 137-142.	1.7	25
9	Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2005, 181, 566-575.	1.5	20
10	Test Your Knowledge: Ten Questions about Schizophrenia. <i>PLoS Medicine</i> , 2005, 2, e175.	3.9	1
11	Olanzapine for schizophrenia. <i>The Cochrane Library</i> , 2005, , CD001359.	1.5	140
12	Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome. <i>European Neuropsychopharmacology</i> , 2006, 16, 459-463.	0.3	6
13	Effects of haloperidol and melatonin on the in situ activity of nigrostriatal tyrosine hydroxylase in male Syrian hamsters. <i>Life Sciences</i> , 2006, 78, 1707-1712.	2.0	3
14	How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. <i>Psychopharmacology</i> , 2007, 195, 285-295.	1.5	49
15	Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia. <i>Journal of Neural Transmission</i> , 2007, 114, 255-259.	1.4	22
16	Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. <i>Human Psychopharmacology</i> , 2008, 23, 455-463.	0.7	43
17	Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 628-638.	0.7	51
18	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 322-328.	1.0	15
19	Association of Adverse Drug Effects With Subjective Well-Being in Patients With Schizophrenia Receiving Stable Doses of Risperidone. <i>Clinical Neuropharmacology</i> , 2009, 32, 250-253.	0.2	10

#	ARTICLE	IF	CITATIONS
20	Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: Results from the Juntendo University Schizophrenia Projects (JUSP). <i>Neuroscience Letters</i> , 2010, 469, 55-59.	1.0	21
21	The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2010, 51, 165-170.	1.5	18
22	Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study. <i>NeuroImage</i> , 2010, 49, 2783-2790.	2.1	98
23	Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1836-1840.	2.5	57
24	Antipsychotic medication for early episode schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD006374.	1.5	19
25	Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 172-178.	0.7	11
26	Insight change and its relationship to subjective well-being during acute atypical antipsychotic treatment in schizophrenia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 687-694.	0.7	7
27	A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 593-601.	0.7	32
28	Effects of Paroxetine on Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 188-192.	1.0	11
29	Evaluation of the factor structure of symptoms in patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 197, 285-289.	1.7	48
30	The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 38, 228-235.	2.5	15
31	Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: A randomized, double-blind, placebo- and haloperidol-controlled study. <i>Journal of Affective Disorders</i> , 2012, 136, 476-484.	2.0	24
32	Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 104, 113-118.	1.3	16
33	Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 633-641.	1.8	15
34	Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2013, 27, 731-741.	2.7	15
35	Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement. <i>Human Psychopharmacology</i> , 2013, 28, 107-116.	0.7	12
36	An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1553.	1.0	2
37	Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER). <i>Psychiatry Investigation</i> , 2013, 10, 407.	0.7	3

#	ARTICLE	IF	CITATIONS
38	Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1655.	1.0	2
39	Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 2339.	1.0	2
40	A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). <i>World Journal of Biological Psychiatry</i> , 2014, 15, 113-121.	1.3	29
41	Effects of Escitalopram on Plasma Concentrations of Aripiprazole and its Active Metabolite, Dehydroaripiprazole, in Japanese Patients. <i>Pharmacopsychiatry</i> , 2014, 47, 101-104.	1.7	4
42	Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 419.	1.0	8
43	Standing postural instability in patients with schizophrenia: Relationships with psychiatric symptoms, anxiety, and the use of neuroleptic medications. <i>Gait and Posture</i> , 2015, 41, 847-851.	0.6	12
44	Deficits in emotion based decision-making in schizophrenia; a new insight based on the Iowa Gambling Task. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 52-59.	2.5	21
45	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 3041-3049.	1.0	10
46	The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model. <i>Psychiatry Research</i> , 2016, 238, 33-39.	1.7	7
47	Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability. <i>Scientific Reports</i> , 2017, 7, 8105.	1.6	6
48	Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2018, 4, 28.	0.4	8
49	Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2541-2544.	1.0	4
50	Meta-analysis of physical activity and effects of social function and quality of life on the physical activity in patients with schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 517-527.	1.8	29
51	A 1.5-Year Longitudinal Study of Social Activity in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 567.	1.3	10
52	Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and testâretest reliability. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 546-550.	0.7	3
53	Smoking Rates and Number of Cigarettes Smoked per Day in Schizophrenia: A Large Cohort Meta-Analysis in a Japanese Population. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 19-27.	1.0	30
54	Japanese Society of Neuropsychopharmacology: âGuideline for Pharmacological Therapy of Schizophreniaâ. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 266-324.	1.1	48
55	The Therapeutic Effect of Edible Horticultural Therapy on Extrapyramidal Symptoms in Patients with Schizophrenia. <i>Hortscience: A Publication of the American Society for Horticultural Science</i> , 2021, 56, 1125-1129.	0.5	1

#	ARTICLE	IF	CITATIONS
56	Effects of combination pharmacotherapy and social skills training for schizophrenia: A randomized controlled trial. Open Journal of Psychiatry, 2013, 03, 273-282.	0.2	1
57	Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacology Bulletin, 2011, 44, 18-31.	0.0	34
59	Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532211396.	1.2	3